The beauty industry buying spree, which recently included e.l.f. Beauty's $1 billion deal for Rhode and Huda Kattan buying back full control of her namesake brand, continues. L’Oréal Groupe has officially agreed to acquire a majority stake in 16-year-old U.K.-based Medik8.
European mid-market private equity firm Inflexion will remain a minority shareholder, per an official announcement.
Founder Elliot Isaacs will continue to serve on the board, "with the current management committee also remaining in place to ensure continuity," according to an official announcement.
Per a Financial Times report last week, the deal could be worth about 1 billion euros, larger than the Rhode deal.
Medik8 is a "dermatological skin care brand, globally renowned for clinically proven age-defying results, without compromise." L’Oréal views the acquisition as an opportunity to boost its Luxe portfolio with "premium science-backed skin care brand with a proven track record of success, with strong potential for global growth." (Medik8 has built a strong business in Europe and has begun to expand its U.S. presence.)
The news comes amid a boom in dermatological beauty, which has risen to prominence at the expense of clean beauty pure players.
It also follows the December 2024 purchase by L'Oreal of K-beauty standout Dr.G.
“We are delighted to welcome Medik8 to the L’Oréal family," said Cyril Chapuy, president of L’Oréal Luxe. "As a premium skin care range, with high levels of proven efficacy at an accessible price point, Medik8 perfectly complements our existing skin care portfolio. We share a strong belief in Medik8's global potential and are excited to embark on this journey together, to build a powerful and impactful brand presence worldwide.”
“This is an exciting day for Medik8,” said Simon Coble, CEO of Medik8. “I am delighted to be joining forces with a company which shares our vision for the brand’s future growth and whose core values align with our deep commitment to science, innovation and above all, results without compromise. I look forward to the next stage in Medik8’s journey, as we work together to bring our innovative products to a wider audience.”
